Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients
The present study is intended to investigate the efficacy and safety of the patients with confirmed advanced pancreatic cancer after treating with the combination of paclitaxel liposome plus S-1.
Advanced Pancreatic Cancer
DRUG: Paclitaxel liposome|DRUG: S-1
Progression free survival, To evaluate the Progression Free Survival of patients with advanced pancreatic cancer after treated with paclitaxel liposome plus S-1., from the date of enrollment to the day of progression or death of any cause, whichever come first, assessed up to 10 months
Overall Response Rate, To evaluate the Overall Response Rate of patients with advanced pancreatic cancer after treated with paclitaxel liposome plus S-1., from the date of enrollment to the day of progression or death of any cause, whichever come first, assessed up to 10 months|overall survival, To evaluate the overall survival of patients with advanced pancreatic cancer after treated with paclitaxel liposome plus S-1., from the date of enrollmen to death of any cause or the end of this trial, whichever come first, assessed up to 10 months|Disease control rate, To evaluate the disease control rate of patients with advanced pancreatic cancer after treated with paclitaxel liposome plus S-1., from the date of enrollment to the day of progression or death of any cause, whichever come first, assessed up to 10 months|Quality of life (Qol), To evaluate the Quality of Life of patients with advanced pancreatic cancer after treated with paclitaxel liposome plus S-1., from the date of enrollmen to death of any cause or the end of this trial, whichever come first, assessed up to 10 months|Adverse events, To evaluate the adverse events of patients with advanced pancreatic cancer after treated with paclitaxel liposome plus S-1., from the date of enrollmen to death of any cause or the end of this trial, whichever come first, assessed up to 10 months
Allocation: Non-randomized Endpoint Classification: Efficacy/ Safety Study Intervention Model: single arm Masking: Open Lable Primary Purpose: Treatment